Nakamoto S - Search Results

1

Systemic immunity markers are associated with clinical outcomes of atezolizumab treatment in patients with triple-negative advanced breast cancer: a retrospective multicenter observational study.

Nakamoto S, Shien T, Itoh M, Yamamoto Y, Ohsumi S, Yoshitomi S, Hikino H, Miyoshi K, Notsu A, Taira N, Doihara H, Ikeda M. Nakamoto S, et al. Clin Exp Med. 2023 Dec;23(8):5129-5138. doi: 10.1007/s10238-023-01230-x. Epub 2023 Oct 30. Clin Exp Med. 2023. PMID: 37904008

2

Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy.

Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Nakamoto S, et al. In Vivo. 2020 May-Jun;34(3):1377-1386. doi: 10.21873/invivo.11917. In Vivo. 2020. PMID: 32354934 Free PMC article.

3

De-escalated Therapy Omitting Anthracyclines for Stage I HER2-positive Breast Cancer: A Retrospective Observational Study.

Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T. Nakamoto S, et al. In Vivo. 2020 Nov-Dec;34(6):3713-3718. doi: 10.21873/invivo.12219. In Vivo. 2020. PMID: 33144488 Free PMC article.

4

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.

Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T, Notsu A. Nakamoto S, et al. Sci Rep. 2021 Mar 18;11(1):6328. doi: 10.1038/s41598-021-85948-2. Sci Rep. 2021. PMID: 33737682 Free PMC article.

5

Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival Benefit.

Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T. Nakamoto S, et al. Anticancer Res. 2021 Jun;41(6):3109-3119. doi: 10.21873/anticanres.15095. Anticancer Res. 2021. PMID: 34083304

6

Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study.

Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Nakamoto S, et al. Sci Rep. 2021 Nov 2;11(1):21454. doi: 10.1038/s41598-021-00711-x. Sci Rep. 2021. PMID: 34728668 Free PMC article.

7

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study.

Nakamoto S, Watanabe J, Ohtani S, Morita S, Ikeda M. Nakamoto S, et al. BMC Cancer. 2022 Jan 3;22(1):31. doi: 10.1186/s12885-021-09137-0. BMC Cancer. 2022. PMID: 34980019 Free PMC article.

8

Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy.

Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T, Kuwahara C. Nakamoto S, et al. Cancer Diagn Progn. 2021 Nov 3;1(5):491-498. doi: 10.21873/cdp.10066. eCollection 2021 Nov-Dec. Cancer Diagn Progn. 2021. PMID: 35403154 Free PMC article.

9

The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer.

Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T, Kuwahara C. Nakamoto S, et al. Cancer Diagn Progn. 2021 Nov 3;1(5):471-478. doi: 10.21873/cdp.10063. eCollection 2021 Nov-Dec. Cancer Diagn Progn. 2021. PMID: 35403159 Free PMC article.

10

Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.

Nakamoto S, Shien T, Iwamoto T, Kubo S, Yamamoto M, Yamashita T, Kuwahara C, Ikeda M. Nakamoto S, et al. Sci Rep. 2024 Apr 30;14(1):9869. doi: 10.1038/s41598-024-60101-x. Sci Rep. 2024. PMID: 38684839 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

479 results

Search Page

Filters